SCHEMBL1240939

SCHEMBL1240939

CS(=O)(=O)NC1CN(C(c2ccc(F)cc2)C(O)(c2cccnc2)c2cccnc2)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 13/20 0.49
KCNH2 Q12809 9/20 0.49
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
KCND3 Q9UK17 1/20 0.40
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 1/20 0.38
EPHX2 P34913 1/20 0.38
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1240800 0.87 KCNA5 (0.52) KCNA5KCNH2KCNE1KCNQ1KCND3
SCHEMBL1242225 0.85 KCNA5 (0.50) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1242334 0.84 KCNA5 (0.49) KCNA5KCNH2KCNE1KCNQ1KCND3
SCHEMBL1242382 0.82 KCNA5 (0.52) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1242857 0.82 KCNA5 (0.54) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1242998 0.82 KCNA5 (0.49) KCNA5KCNH2KCNE1KCNQ1KCND3
SCHEMBL1242756 0.82 KCNA5 (0.58) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1243184 0.81 KCNA5 (0.57) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1243568 0.80 KCNA5 (0.54) KCNA5KCNH2POLBNPSR1CYP3A4
SCHEMBL1242302 0.80 KCNA5 (0.54) KCNA5KCNH2POLBNPSR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885KCNE1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.